SCHEMBL31358222

SCHEMBL31358222

Cn1ncc2cc(N)ncc21

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIK3CB P42338 1/20 0.55
▸ CDC7 O00311 1/20 0.43
▸ PDPK1 O15530 1/20 0.41
▸ MAPK1 P28482 3/20 0.39
▸ NOS3 P29474 1/20 0.39
▸ NOS1 P29475 1/20 0.39
▸ NOS2 P35228 1/20 0.39
▸ MPO P05164 2/20 0.38
▸ TRPM5 Q9NZQ8 1/20 0.37
▸ SRC P12931 3/20 0.36
▸ USP7 Q93009 1/20 0.36
▸ FGFR1 P11362 1/20 0.36
▸ CYP11B2 P19099 1/20 0.36
▸ TRPA1 O75762 1/20 0.36
▸ PI4KA P42356 1/20 0.35
▸ PI4K2B Q8TCG2 1/20 0.35
▸ PI4K2A Q9BTU6 1/20 0.35
▸ PI4KB Q9UBF8 1/20 0.35
▸ CHEK1 O14757 1/20 0.34
▸ AURKA O14965 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19648359 0.84 PIK3CB (0.46) PIK3CBCDC7PDPK1NOS3NOS1
SCHEMBL21958683 0.78 MAPK1 (0.43) CDC7MAPK1TRPM5USP7CYP11B2
SCHEMBL7920620 0.78 CYP1A2 (0.42) CDC7MAPK1TRPM5CYP11B2TRPA1
SCHEMBL12535873 0.76 TRPM5 (0.43) CDC7MAPK1TRPM5SRCCYP11B2
SCHEMBL12384973 0.76 MAPK1 (0.39) CDC7MAPK1TRPM5CYP11B2TRPA1
SCHEMBL30754802 0.76 MAPK1 (0.39) CDC7MAPK1TRPM5CYP11B2TRPA1
SCHEMBL27274089 0.74 AR (0.44) CDC7MAPK1CHEK1AURKADAPK3
SCHEMBL10183335 0.73 MAPK1 (0.39) CDC7MAPK1TRPM5SRCCYP11B2
SCHEMBL10233457 0.73 TRPM5 (0.38) CDC7MAPK1TRPM5USP7CYP11B2
SCHEMBL15341870 0.73 MAPK1 (0.43) PIK3CBCDC7MAPK1TRPM5CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4727647-A1 GLYCOGEN SYNTHASE KINASE 3 INHIBITORS AND USES THEREOF The Broad Institute Inc. (US) 2026-04-22 — — EP disclosed
US-20260103465-A1 GLYCOGEN SYNTHASE KINASE 3 INHIBITORS AND USES THEREOF THE BROAD INSTITUTE, INC. (US) 2026-04-16 — — US disclosed
WO-2024259178-A1 GLYCOGEN SYNTHASE KINASE 3 INHIBITORS AND USES THEREOF THE BROAD INSTITUTE, INC. (US) 2024-12-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260103465-A1 GLYCOGEN SYNTHASE KINASE 3 INHIBITORS AND USES THEREOF GSK3A, GSK3B, GYS2 PIK3CB 1210/4885CDC7 1061/4885PDPK1 408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback